Investor Relations

OncoSec CEO Letter to Shareholders

View Letter

Recent Event

Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting

Latest Financial Results

FY 2019

Fiscal Year Ended Jul 31, 2019

Latest Annual Filing

For Fiscal Year Ending Jul 31, 2019

Company Overview

OncoSec Medical Incorporated is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec's lead immunotherapy investigational product candidate – TAVO™ (tavokinogene telseplasmid) – enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO™ as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders. Results from recently completed clinical studies of TAVO™ have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach. In addition to TAVO™, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its new Visceral Lesion Applicator (VLA), to target deep visceral lesions, such as liver, lung or pancreatic lesions.

Investor Contact Information

Company

OncoSec Medical Incorporated
24 Main St.
Pennington, NJ 08534

Investor Relations

T: 855-ONCOSEC (855-662-6732)
investors@oncosec.com

Transfer Agent

Nevada Agency and Transfer Company
50 W. Liberty St.
Suite 880
Reno, NV 89501
T: 775-322-0626
info@natco.org
www.natco.org

Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.